Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: AREG

Summary for AREG

Gene information	Gene symbol	AREG
	Ensembl ID	ENSG00000109321
	Entrez ID	374
	Gene name	amphiregulin
	Synonyms	AR\|AREGB\|SDGF
	Gene type	protein_coding
	UniProtAcc	P15514

Top

Dataset with differentially expressed gene: AREG

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	-1.70116	1.57e-02
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.585889	1.45e-31
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.05813	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.377402	2.41e-11
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.270174	4.43e-11
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	-0.749152	5.75e-04
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.685791	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.787128	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	cDCs	0.649909	9.14e-07
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	cDCs	0.33017	2.95e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	2.50144	2.21e-04
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mast cells	2.8822	5.12e-05
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	0.36486	1.85e-17
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.92141	1.46e-12
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.751788	1.35e-26
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	1.38162	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	pDCs	1.84869	1.79e-02
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.915806	8.18e-19
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.495996	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.853745	4.34e-22
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	1.10632	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.798904	3.39e-12
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	-1.36106	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	0.481522	9.86e-16
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	1.36438	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-1.88184	0.00e+00
GSE164897_Vem	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib	NA	Malignant cells	0.730063	0.00e+00

Top

Expression of AREG in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to AREG

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Gene symbol	Cell type with DEG	Interaction ID	Interacting pair	Gene A	Gene B	Integrin	Interacting cell type1	Interacting cell type2	Dataset	Timepoint	Condition
AREG	pDCs	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	pDCs	Malignant cells	GSE207422_Sin	post	resistant
AREG	Mast cells	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Mast cells	Malignant cells	GSE207422_Sin	post	resistant
AREG	pDCs	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	pDCs	Malignant cells	GSE207422_Sin	post	sensitive
AREG	Mast cells	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Mast cells	Malignant cells	GSE207422_Sin	post	sensitive
AREG	Malignant cells	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Malignant cells	Endothelial cells	GSE207422_Tor	post	resistant
AREG	Malignant cells	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Malignant cells	Malignant cells	GSE207422_Tor	post	resistant
AREG	Malignant cells	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Mast cells	Malignant cells	GSE207422_Tor	post	resistant
AREG	Malignant cells	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Mono/Macro	Malignant cells	GSE207422_Tor	post	resistant
AREG	Malignant cells	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	pDCs	Malignant cells	GSE207422_Tor	post	resistant
AREG	Mono/Macro	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Mono/Macro	Endothelial cells	GSE207422_Tor	post	resistant
AREG	Mono/Macro	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Mono/Macro	Malignant cells	GSE207422_Tor	post	resistant
AREG	Malignant cells	CPI-SS052119104	AREG_EGFR	AREG	EGFR	False	Mast cells	Malignant cells	GSE207422_Tor	post	sensitive

Page: 1

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
AREG	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating AREG

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
AREG	hsa-miR-1185-1-3p	91.4277	NM_001657
AREG	hsa-let-7f-2-3p	91.4277	NM_001657
AREG	hsa-miR-1185-2-3p	91.4277	NM_001657
AREG	hsa-miR-4504	90.2667	NM_001657
AREG	hsa-miR-12136	89.3757	NM_001657
AREG	hsa-miR-486-5p	84.5704	NM_001657

Page: 1

Top

Motifs and transcription factors (TFs) regulating AREG

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
AREG	transfac_pro__M01783	SP2 (directAnnotation).
AREG	metacluster_111.3	ATF1; ATF3; CREB1; CREB1; CREB1; CREB1; CREB1; CREM; CREM; CREM; CREM; E4F1; E4F1 (directAnnotation). CREB1; CREB1; CREM; JDP2 (inferredBy_Orthology).
AREG	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
AREG	kznf__ZNF548_Imbeault2017_RP_RCADE	ZNF548 (directAnnotation).
AREG	transfac_public__M00039	CREB1 (directAnnotation).
AREG	transfac_pro__M00691	ATF1 (directAnnotation).
AREG	transfac_pro__M04746	E2F1 (directAnnotation).
AREG	taipale_cyt_meth__KLF3_NRCCGCAGCCCN_FL_meth_repr	KLF3 (directAnnotation).
AREG	taipale_tf_pairs__CUX1_HOXA13_NYMRTAAANATYGATN_CAP_repr	CUX1; HOXA13 (directAnnotation).
AREG	metacluster_9.47	PAX7 (inferredBy_Orthology).
AREG	taipale_tf_pairs__CUX1_HOXB13_SYMRTAAANATYGATN_CAP	CUX1; HOXB13 (directAnnotation).
AREG	nitta__CG18619_TCGAAG20NGA_KH_RTGACGTCAT_m1_c3u	CREBL2 (inferredBy_Orthology).
AREG	kznf__ZNF211_Imbeault2017_OM_RCADE	ZNF211 (directAnnotation).
AREG	tfdimers__MD00234	CDX2; TFAP2C (directAnnotation).
AREG	homer__DGCACACGTG_MNT	MNT (directAnnotation).
AREG	cisbp__M00938	MAX (directAnnotation).
AREG	transfac_pro__M06000	ZNF233 (directAnnotation).
AREG	transfac_pro__M06962	HES7 (inferredBy_Orthology).
AREG	transfac_public__M00078	MECOM; RUNX1 (directAnnotation).
AREG	taipale_tf_pairs__JUN_ATGACGTCAT_HT	JUN (directAnnotation).
AREG	transfac_pro__M02113	POU2AF1 (directAnnotation).
AREG	transfac_pro__M07420	HES1 (directAnnotation).
AREG	tfdimers__MD00086	ARID3A; YY1 (directAnnotation).
AREG	transfac_pro__M06148	ZNF41 (directAnnotation).
AREG	metacluster_178.17	ZNF775 (directAnnotation).
AREG	taipale_cyt_meth__JUND_NRTGACGCATN_eDBD_repr	JUND (directAnnotation).
AREG	transfac_pro__M06032	ZNF727 (directAnnotation).
AREG	metacluster_22.12	NFE2; NFE2L1 (directAnnotation).
AREG	metacluster_22.30	NFE2L2 (directAnnotation).
AREG	metacluster_157.2	ATF3; ATF3; ATF3; BACH1; BACH1; BACH1; BACH2; BACH2; BACH2; BACH2; BATF; BATF; BCL11A; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; MAF; MAFB; MAFF; MAFG; MAFK; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2; NFE2L3; ZNF3; ZSCAN5C (directAnnotation). FOSL1; JUN; JUN; JUN; JUNB; JUNB; JUND (inferredBy_Orthology).
AREG	transfac_pro__M05765	ZNF684 (directAnnotation).
AREG	hocomoco__ZSCA4_HUMAN.H11MO.0.D	ZSCAN4 (directAnnotation).
AREG	kznf__PRDM1_modENCODE.2_ChIP-seq	PRDM1 (directAnnotation).
AREG	transfac_pro__M06661	ZNF426 (directAnnotation).
AREG	kznf__ZNF716_Imbeault2017_RP_RCADE	ZNF716 (directAnnotation).
AREG	transfac_pro__M05886	ZNF619 (directAnnotation).
AREG	kznf__ZNF136_Najafabadi2015_ChIP-seq	ZNF136 (directAnnotation).
AREG	transfac_pro__M06178	ZNF81 (directAnnotation).
AREG	transfac_pro__M05509	PLAGL1 (directAnnotation).
AREG	transfac_pro__M06184	ZNF85 (directAnnotation).
AREG	transfac_pro__M06614	ZNF594 (directAnnotation).
AREG	hocomoco__BPTF_HUMAN.H11MO.0.D	BPTF (directAnnotation).
AREG	metacluster_160.20	JUND; PRDM15 (directAnnotation).
AREG	metacluster_151.1	KAT7; PML; SMAD5; TAF1; ZFP37; ZGPAT; ZNF519; ZNF519; ZNF571; ZNF770; ZNF770; ZNF770; ZSCAN22; ZSCAN22 (directAnnotation).
AREG	jaspar__MA0185.1	DEAF1 (inferredBy_Orthology).
AREG	kznf__ZNF213_Schmitges2016_RCADE	ZNF213 (directAnnotation).
AREG	metacluster_151.2	ZNF23 (directAnnotation).
AREG	metacluster_85.7	ZSCAN29; ZSCAN29 (directAnnotation).
AREG	kznf__ZNF786_Imbeault2017_OM_MEME	ZNF786 (directAnnotation).
AREG	tfdimers__MD00429	ARID3A; IKZF2 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."